Tetraphase Pharmaceuticals Inc. (TTPH) Receives $7.14 Average Price Target from Brokerages

Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) has earned a consensus recommendation of “Hold” from the twelve brokerages that are currently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and six have assigned a buy rating to the company. The average 1-year target price among brokers that have issued ratings on the stock in the last year is $7.14.

Several analysts have weighed in on the stock. ValuEngine upgraded shares of Tetraphase Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Tetraphase Pharmaceuticals in a research note on Friday, May 4th. Gabelli upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Thursday, March 29th. BMO Capital Markets reiterated a “market perform” rating and set a $3.00 target price (up previously from $2.75) on shares of Tetraphase Pharmaceuticals in a research note on Thursday, March 8th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research note on Wednesday, March 7th.

Several institutional investors and hedge funds have recently made changes to their positions in the company. BlackRock Inc. boosted its holdings in shares of Tetraphase Pharmaceuticals by 21.2% during the fourth quarter. BlackRock Inc. now owns 4,044,340 shares of the biopharmaceutical company’s stock valued at $25,479,000 after acquiring an additional 707,296 shares during the period. Millennium Management LLC boosted its holdings in shares of Tetraphase Pharmaceuticals by 30.8% during the fourth quarter. Millennium Management LLC now owns 2,715,025 shares of the biopharmaceutical company’s stock valued at $17,105,000 after acquiring an additional 639,467 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Tetraphase Pharmaceuticals by 28.8% during the first quarter. Dimensional Fund Advisors LP now owns 1,832,741 shares of the biopharmaceutical company’s stock valued at $5,627,000 after acquiring an additional 409,567 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of Tetraphase Pharmaceuticals by 77.6% during the fourth quarter. Renaissance Technologies LLC now owns 592,493 shares of the biopharmaceutical company’s stock valued at $3,733,000 after acquiring an additional 258,908 shares during the period. Finally, Candriam Luxembourg S.C.A. boosted its holdings in shares of Tetraphase Pharmaceuticals by 3.1% during the first quarter. Candriam Luxembourg S.C.A. now owns 520,613 shares of the biopharmaceutical company’s stock valued at $1,598,000 after acquiring an additional 15,613 shares during the period. 44.66% of the stock is owned by institutional investors.

TTPH stock traded up $0.02 during trading on Friday, hitting $4.01. 1,244,600 shares of the company’s stock traded hands, compared to its average volume of 1,151,592. Tetraphase Pharmaceuticals has a 52 week low of $2.05 and a 52 week high of $8.75. The firm has a market cap of $221.86 million, a price-to-earnings ratio of -1.52 and a beta of 2.64.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its earnings results on Thursday, May 3rd. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, beating the consensus estimate of ($0.46) by $0.04. Tetraphase Pharmaceuticals had a negative net margin of 1,061.06% and a negative return on equity of 85.70%. The firm had revenue of $1.89 million during the quarter, compared to analyst estimates of $1.88 million. equities research analysts predict that Tetraphase Pharmaceuticals will post -1.56 earnings per share for the current fiscal year.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is eravacycline, a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat resistant and multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply